HK1021025A1 - Process for in vitro detecting the presence or absence of antibodies to anti-tissue transglutinase from body fluids. - Google Patents

Process for in vitro detecting the presence or absence of antibodies to anti-tissue transglutinase from body fluids.

Info

Publication number
HK1021025A1
HK1021025A1 HK99106049A HK99106049A HK1021025A1 HK 1021025 A1 HK1021025 A1 HK 1021025A1 HK 99106049 A HK99106049 A HK 99106049A HK 99106049 A HK99106049 A HK 99106049A HK 1021025 A1 HK1021025 A1 HK 1021025A1
Authority
HK
Hong Kong
Prior art keywords
ttg
diagnosis
body fluids
therapy control
antibodies
Prior art date
Application number
HK99106049A
Other languages
English (en)
Inventor
Detlef Schuppan
Walburga Dieterich
Tobias Ehnis
Original Assignee
Detlef Schuppan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7801172&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1021025(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Detlef Schuppan filed Critical Detlef Schuppan
Publication of HK1021025A1 publication Critical patent/HK1021025A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1025—Acyltransferases (2.3)
    • C12N9/104—Aminoacyltransferases (2.3.2)
    • C12N9/1044—Protein-glutamine gamma-glutamyltransferase (2.3.2.13), i.e. transglutaminase or factor XIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Rheumatology (AREA)
  • Rehabilitation Therapy (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
HK99106049A 1996-07-18 1999-12-22 Process for in vitro detecting the presence or absence of antibodies to anti-tissue transglutinase from body fluids. HK1021025A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19630557A DE19630557C2 (de) 1996-07-18 1996-07-18 Verfahren zum Nachweis von Antikörpern aus Körperflüssigkeiten durch eine Immunreaktion mit Gewebe-Transglutaminase (tTG) sowie die Verwendung von tTG in Diagnose und Therapie
PCT/EP1997/003740 WO1998003872A2 (de) 1996-07-18 1997-07-14 IMMUNOLOGISCHES NACHWEISVERFAHREN VON ANTIKÖRPERN, DIE GEGEN GEWEBE-TRANSGLUTAMINASE (tTG) GERICHTET SIND, VERWENDUNG VON tTG ZUR DIAGNOSE UND THERAPIEKONTROLLE SOWIE ORALES PHARMAZEUTISCHES MITTEL ENTHALTEND tTG

Publications (1)

Publication Number Publication Date
HK1021025A1 true HK1021025A1 (en) 2000-05-26

Family

ID=7801172

Family Applications (1)

Application Number Title Priority Date Filing Date
HK99106049A HK1021025A1 (en) 1996-07-18 1999-12-22 Process for in vitro detecting the presence or absence of antibodies to anti-tissue transglutinase from body fluids.

Country Status (22)

Country Link
US (2) US6319726B1 (xx)
EP (1) EP0912898B1 (xx)
CN (1) CN1138146C (xx)
AT (1) ATE210296T1 (xx)
AU (1) AU718797B2 (xx)
BR (1) BR9710500B1 (xx)
CA (1) CA2260769C (xx)
CZ (1) CZ291662B6 (xx)
DE (2) DE19630557C2 (xx)
DK (1) DK0912898T3 (xx)
ES (1) ES2131038T3 (xx)
GR (1) GR990300020T1 (xx)
HK (1) HK1021025A1 (xx)
HU (1) HU228479B1 (xx)
IL (1) IL128042A (xx)
NO (1) NO321466B1 (xx)
NZ (1) NZ333744A (xx)
PL (1) PL189091B1 (xx)
PT (1) PT912898E (xx)
SI (1) SI9720044B (xx)
SK (1) SK284410B6 (xx)
WO (1) WO1998003872A2 (xx)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3596199A (en) * 1998-05-06 1999-11-23 Kobenhavns Universitet Treatment of celiac disease
DE60011622T2 (de) * 1999-06-28 2005-09-08 Immundiagnostik Ag Diagnose der glutensensibilitätsenteropathie und anderer autoimmunerkrangungen
US6703208B1 (en) 1999-10-20 2004-03-09 Immco Diagnostics Immunological assay for detection of antibodies in celiac disease
AU1966201A (en) * 1999-10-20 2001-04-30 Immco Diagnostics Immunological assay for detection of antibodies in celiac disease
CU22968A1 (es) * 2000-06-07 2004-07-14 Ct Ingenieria Genetica Biotech Procedimiento para la detección de anticuerpos anti transglutaminasa con utilidad en el diagnóstico de la enfermedad celíaca
GB0103024D0 (en) * 2001-02-07 2001-03-21 Rsr Ltd Assay for Autoantibodies to tissue transglutaminase
FI20010868A0 (fi) * 2001-04-25 2001-04-25 Markku Maeki Menetelmä ja välineet gluteenin indusoimien tautien havaitsemiseksi
KR100488131B1 (ko) * 2001-07-07 2005-05-06 (주)푸드바이오테크 알레르기 진단용 단백질 칩과 알레르기 유발원의 검출방법 및 알레르기 유발 항체의 검출 방법
GB0117870D0 (en) * 2001-07-21 2001-09-12 Univ Nottingham Trent Method of diagnosis and kit of parts therefor
DK1572127T4 (da) 2002-02-14 2014-11-24 Univ Leland Stanford Junior Enzymbehandling af fødevarer til cøliaki
US8143210B2 (en) * 2002-02-14 2012-03-27 The Board Of Trustees Of The Leland Stanford Junior University Enzyme treatment of foodstuffs for celiac sprue
US7320788B2 (en) * 2002-02-14 2008-01-22 The Board Of Trustees Of The Leland Stanford Junior University Enzyme treatment of foodstuffs for Celiac Sprue
US7202216B2 (en) * 2002-05-14 2007-04-10 The Board Of Trustees Of The Leland Stanford Junior University Drug therapy for celiac sprue
US7265093B2 (en) * 2002-05-14 2007-09-04 The Board Of Trustees Of The Leland Stanford Junior University Drug therapy for Celiac Sprue
EP1507549A4 (en) * 2002-05-14 2009-07-01 Univ Leland Stanford Junior MEDICAMENT THERAPY AGAINST CELIAC SPRUE
US7462688B2 (en) * 2002-05-14 2008-12-09 The Board Of Trustees Of The Leland Stanford Junior University Peptides for diagnostic and therapeutic methods for celiac sprue
CA2502700C (en) * 2002-11-20 2017-01-17 Chaitan Khosla Diagnostic method for celiac sprue
US7579313B2 (en) * 2003-11-18 2009-08-25 The Board Of Trustees Of The Leland Stanford Junior University Transglutaminase inhibitors and methods of use thereof
US7534426B2 (en) * 2004-04-26 2009-05-19 The Board Of Trustees Of The Leland Stanford Junior University Glutenase enzyme assays
US7563864B2 (en) * 2004-04-26 2009-07-21 Celiac Sprue Research Foundation Prolyl endopeptidase mediated destruction of T cell epitopes in whole gluten
US7628985B2 (en) * 2004-04-26 2009-12-08 The Board Of Regents Of The Leland Stanford Junior University Therapeutic enzyme formulations and uses thereof in celiac sprue and/or dermatitis herpetoformis
US20080038760A1 (en) * 2004-06-08 2008-02-14 Method For Decting Anti-Transglutaminase Antibodies Method for Detecting Anti-Transglutaminase Antibodies
US20090305303A1 (en) * 2006-07-25 2009-12-10 Cecile Besson Duvanel immunochromatography device for the diagnosis of diseases in a sample
US8058019B2 (en) * 2007-01-26 2011-11-15 Ga Generic Assays Gmbh Method for assaying antibodies in body fluids by immune reaction with glycoprotein 2 (GP2) from zymogenic granules of the pancreas for the differential diagnosis of inflammatory intestinal diseases and chronic pancreatitis
AU2008229448B2 (en) * 2007-03-16 2013-01-24 The Board Of Trustees Of The Leland Stanford Junior University Combination enzyme therapy for digestion of dietary gluten
ATE511651T1 (de) 2007-04-06 2011-06-15 Zedira Gmbh Transglutaminase 6 als diagnostischer indikator für autoimmunerkrankungen
HU0900199D0 (en) * 2009-04-01 2009-06-29 Debreceni Egyetem Diagnosis of gluten-induced autoimmune diseases
FR2949782B1 (fr) * 2009-09-04 2015-10-16 Isp Investments Inc Peptide activateur de la transglutaminase et composition cosmetique ou pharmaceutique le contenant.
WO2013119845A1 (en) 2012-02-07 2013-08-15 Vibrant Holdings, Llc Substrates, peptide arrays, and methods
DE102012007510A1 (de) 2012-04-17 2013-10-17 Aesku.Diagnostics GmbH & Co. KG Verfahren zur Präsymptomatischen Diagnostik von Zöliakie und Glutensensitivität
HUE043698T2 (hu) 2012-04-17 2019-09-30 Aeneas Gmbh & Co Kg Eljárás cöliákia és gluténérzékenység tünetek elõtti diagnosztizálására
US10006909B2 (en) 2012-09-28 2018-06-26 Vibrant Holdings, Llc Methods, systems, and arrays for biomolecular analysis
US10286376B2 (en) 2012-11-14 2019-05-14 Vibrant Holdings, Llc Substrates, systems, and methods for array synthesis and biomolecular analysis
JP5981667B2 (ja) 2013-02-15 2016-08-31 ヴィブラント ホールディングス リミテッド ライアビリティ カンパニー 増幅された電気化学発光検出のための方法および組成物
CN104090102B (zh) * 2014-06-13 2016-08-17 江南大学 冷冻鱼糜中微生物谷氨酰胺转胺酶elisa检测方法
JP6887945B2 (ja) 2014-09-10 2021-06-16 ヴィブラント ホールディングス リミテッド ライアビリティ カンパニー セリアック病に関するペプチドマイクロアレイおよび新規バイオマーカー
WO2018218250A2 (en) 2017-05-26 2018-11-29 Vibrant Holdings, Llc Photoactive compounds and methods for biomolecule detection and sequencing
CN110055235A (zh) * 2019-05-14 2019-07-26 深圳市亚辉龙生物科技股份有限公司 用于转谷氨酰胺酶抗体检测的抗原及其制备方法、试剂盒及检测方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL155894B1 (en) * 1987-12-23 1992-01-31 Przed Zagraniczne W Polsce Pla Test for assessing gluten-dependent enteropathies
DE3829524A1 (de) * 1988-08-31 1990-03-01 Behringwerke Ag Verwendung von transglutaminasen als immunsuppressiva
DE19520480C2 (de) 1995-06-03 1997-04-30 Univ Leipzig Immunochemisches Testmaterial und Enzymimmunoassay zur Diagnostik von Zöliakie und verwandten Eiweißintoleranzen
US5716794A (en) * 1996-03-29 1998-02-10 Xybernaut Corporation Celiac antigen

Also Published As

Publication number Publication date
NO990190D0 (no) 1999-01-15
DE19630557A1 (de) 1998-01-29
CZ291662B6 (cs) 2003-04-16
BR9710500B1 (pt) 2009-05-05
SK6799A3 (en) 2000-05-16
NO321466B1 (no) 2006-05-15
AU718797B2 (en) 2000-04-20
US20020076834A1 (en) 2002-06-20
GR990300020T1 (en) 1999-06-30
EP0912898B1 (de) 2001-12-05
CN1138146C (zh) 2004-02-11
CZ11799A3 (cs) 1999-07-14
HUP0202779A3 (en) 2009-07-28
ATE210296T1 (de) 2001-12-15
SK284410B6 (sk) 2005-03-04
HUP0202779A2 (hu) 2002-12-28
CN1225723A (zh) 1999-08-11
ES2131038T3 (es) 2002-09-01
DE19630557C2 (de) 1998-07-02
HU228479B1 (en) 2013-03-28
IL128042A0 (en) 1999-11-30
NO990190L (no) 1999-03-15
CA2260769C (en) 2005-09-06
WO1998003872A3 (de) 1998-03-12
ES2131038T1 (es) 1999-07-16
DE59705683D1 (de) 2002-01-17
AU4201197A (en) 1998-02-10
PL189091B1 (pl) 2005-06-30
DK0912898T3 (da) 2002-04-08
US6319726B1 (en) 2001-11-20
SI9720044B (sl) 2003-02-28
PL331203A1 (en) 1999-07-05
IL128042A (en) 2007-06-17
PT912898E (pt) 2002-05-31
BR9710500A (pt) 2000-01-18
EP0912898A2 (de) 1999-05-06
NZ333744A (en) 2000-03-27
SI9720044A (sl) 1999-08-31
WO1998003872A2 (de) 1998-01-29
CA2260769A1 (en) 1998-01-29

Similar Documents

Publication Publication Date Title
HK1021025A1 (en) Process for in vitro detecting the presence or absence of antibodies to anti-tissue transglutinase from body fluids.
EP0909814A3 (en) Use of protein kinases for the diagnosis and treatment of Alzheimer's disease
GB9224584D0 (en) Use of outer membrane protein d15 and its peptides as vaccine against haempohilus influenzae diseases
NZ330887A (en) Monoclonals and polyclonals antibodies for the diagnosis of breast cancer
IL176076A0 (en) Ligands,including antibodies showing, reactivity against endocrine cells
DE59102225D1 (de) Ultraschall-Kontrastmittel, Verfahren zu ihrer Herstellung und Verwendung derselben als Diagnostika und Therapeutika.
SE8902638L (sv) Stabiliserade protein- eller peptidkonjugat
WO1998045328A3 (en) Compositions and methods for the treatment and diagnosis of breast cancer
EP0674661A4 (en) TITRATION AND TREATMENT FOR DEMYELINIZING DISEASES SUCH AS MULTIPLE SCLEROSIS.
HUT63334A (en) Process for producing sclerosis multiplex t-cell receptor
WO1998039034A3 (de) Verwendung von anti-cd44 antikörper enthaltenden präparationen zur behandlung bestimmter tumore und zur unterdrückung von immunreaktionen
EP0937982A3 (de) Diagnostikum und Therapeutikum zur Behandlung der autoimmunen Hepatitis
WO2004006898A3 (en) Use of compounds capable of inhibiting the proteolytic processing of semaphorins for prevention, treatment, diagnosis and prognosis of an invasive disease
WO1991010735A3 (fr) Recepteur humain de la tsh. sequence codant pour ce recepteur
WO2001021653A3 (en) Ovarian tumor antigen and methods of use therefor
AU653332B2 (en) Synthetic peptides which contain sequences from factor VIIa, and the use thereof
WO1996002272A3 (en) Treatment of autoimmune diseases
CA2151945A1 (en) Assay and treatment for demyelinating diseases such as multiple sclerosis

Legal Events

Date Code Title Description
PF Patent in force
PE Patent expired

Effective date: 20170713